Table 1.
Demographic and clinical characteristics of patients with SSc and healthy controls
| Cont | SSc | p (SSc-Cont) | Diffuse | Limited | p (Diff-Lim) | |
|---|---|---|---|---|---|---|
| N | 25 | 49 | 32 | 17 | ||
| Female, N (%) | 21(84) | 35 (71) | 0.4a | 21 (66) | 14 (82) | 0.37a |
| Age (years), mean (SD;IQR) | 46(12;37-54) | 52 (14; 46–62) | 0.09b | 49 (14; 43–58) | 56 (13; 52–63) | 0.08b |
| White, N (%) | 14(56) | 32 (65) | 0.6a | 19 (59) | 13 (76) | 0.38a |
| mRSS, mean (SD;IQR) | N/A | 14 (11; 4.8–23) | N/A | 18 (10; 9–26) | 6.5 (6.1;3–6) | 0.0001b |
| Disease duration (years), mean (SD;IQR) | N/A | 7.8 (4.9;3.9–12) | N/A | 6.3 (3.7;3.3–8) | 10 (5.8; 5–15) | 0.02b |
| Interstitial lung disease, N (%) | N/A | 19 (40) | N/A | 17 (57) | 2 (12) | 0.007a |
| Immunosuppressive agent, N (%) | N/A | 14 (29) | N/A | 10 (31) | 4 (24) | 0.81a |
| Anti-centromere Ab, N (%) | N/A | 7 (14) | N/A | 1 (3.1) | 6 (35) | 0.008a |
| Anti-topoisomerase Ab, N (%) | N/A | 13 (27) | N/A | 10 (31) | 3 (18) | 0.49a |
| RNA polymerase Ab, N (%) | N/A | 12 (24) | N/A | 11 (34) | 1 (5.9) | 0.06a |
| Ribonucleoprotein Ab, N (%) | N/A | 3 (6.1) | N/A | 2 (6.2) | 1 (5.9) | 1.0a |
aBy χ2 test
bBy Wilcoxon-Mann-Whitney rank sum test